GLP-1 daim ntawv thov kev kho mob rau tsiaj mob ntshav qab zib

 

GLP-1 Txhaj

1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
(2) Tablet
(3) Capsule
(4) Txhaj tshuaj
(5) Ua kua dej
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
Internal Code: BM-3-094
GLP-1 CAS Nr .: 87805-34-3
Lub khw tseem ceeb: Tebchaws Asmeskas, Australia, Brazil, Nyiv, Lub Tebchaws Yelemees, Indonesia, UK, New Zealand, Canada thiab lwm yam.
Chaw tsim tshuaj paus: BLOOM TECH Xi'an Hoobkas
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4

Peb muab GLP-1 Txhaj Tshuaj, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia tshwj xeeb thiab cov ntaub ntawv khoom.

Khoom siv:https://www.bloomtechz.com/oem-odm/injection/glp-1-injections.html

Thaum Lub Peb Hlis 12, 2026, Lilly tau tshaj tawm cov lus ceeb toom rau pej xeem txog qhov muaj feem cuam tshuam txog kev nyab xeeb cuam tshuam nrog kev sib xyaw ntawm tirzepatide thiab vitamin B12.

 

Ua raws li nws txoj kev cog lus rau kev nyab xeeb ntawm tus neeg mob, Lilly tau ua qhov kev sim ntawm cov khoom muag hauv Asmeskas kev lag luam uas muaj kev sib xyaw ntawm tiltrotide thiab B12 (qee zaum hu ua methylcobalamin, hydroxocobalamin, lossis cyanocobalamin). Nws tau pom los ntawm kev ntsuam xyuas tias cov tshuaj tiv thaiv ntawm tilpotide thiab B12 tsim cov impurities tseem ceeb.

Cov impurities tsim los ntawm kev sib cuam tshuam ntawm B12 thiab tiltrotide yog hais txog, raws li tam sim no tsis muaj kev paub txog nws luv luv - lub sij hawm thiab ntev - lub sij hawm cuam tshuam rau tib neeg lub cev, muaj peev xwm cuam tshuam rau cov tshuaj khi GLP-1 thiab GIP receptors, toxicity, lub cev tiv thaiv kab mob, nrog rau kev nqus, kev faib tawm, metabolism, thiab kev tso tawm.

 

Tilpotide yeej tsis tau kawm ua ke nrog B12, thiab cov chaw muag tshuaj sib xyaw ua ke uas tsim cov tshuaj sib xyaw no tsis tas yuav saib xyuas lossis tshaj tawm cov xwm txheej tsis zoo, yog li cov kev pheej hmoo ntawm cov neeg mob tsis paub meej. Cov neeg uas siv tilbopeptide-B12 cov khoom lag luam los ntawm cov chaw muag tshuaj sib xyaw, cov tuam txhab tshuaj kho mob, chaw kho mob, lossis lwm txoj hauv kev yuav tsum paub tias lawv yuav siv cov khoom uas tsis paub txog kev pheej hmoo thiab muaj peev xwm txaus ntshai. Lilly tau tshaj tawm cov kev tshawb pom saum toj no rau US FDA thiab pom zoo tias cov neeg mob uas siv cov khoom tsis zoo li no hu rau tus kws kho mob rau kev sab laj thiab kev sib tham txog lwm txoj kev kho mob.

Thaum Lub Ob Hlis 4, 2026, Yinnuo Pharmaceutical tau tshaj tawm tias daim ntawv thov rau kev sim tshuaj ntsuam xyuas ntawm nws cov khoom tseem ceeb, Esupagludide, rau kev kho mob ntshav qab zib tus tsiaj, raws li cov tshuaj kho tsiaj tshiab, tau lees paub los ntawm Ministry of Agriculture thiab xav tias yuav pib qhov kev sim tshuaj ntsuam xyuas hauv peb lub hlis twg xyoo 2026.

 

Esupagllutide yog ib tiam tshiab ntawm tib neeg ntev heev - ua GLP-1 tshuaj nyob hauv lub ntiaj teb. Nws lub ntsiab kom zoo dua yog nyob rau hauv kev siv cov noob caj noob ces engineering recombinant protein technology los tsim ib tug dual molecular qauv los ntawm tshwj xeeb pob khawm kev twb kev txuas thiab lgG2 fusion protein, uas ua rau nws muaj ib tug muaj zog affinity rau GLP-1 receptor, thiab yog qeeb degraded los ntawm enzymes thiab lim los ntawm ob lub raum hauv vivo. Nws tuaj yeem ua tiav ib nrab-lub neej ntawm 204 teev hauv cov neeg mob ntshav qab zib hom 2. Nws txhawb kev txhaj tshuaj subcutaneous txhua 1-2 lub lis piam, muab kev txiav txim siab rau kev ua tau zoo thiab kev siv tshuaj yooj yim,

Thaum Lub Ib Hlis 2025, esupagglutide tau pom zoo los ua lag luam hauv Suav teb rau kev kho mob rau cov neeg laus mob ntshav qab zib hom 2, suav nrog cov tshuaj ib leeg thiab cov neeg mob uas tseem tswj hwm cov ntshav qabzib tsis zoo tom qab tau txais kev kho mob metformin, thiab txhaj tshuaj subcutaneous ib zaug ib lim tiam. Nyob rau hauv tib lub xyoo, cov khoom lag luam tau ua tiav nyob rau hauv cov ntawv pov hwm kho mob los ntawm kev sib tham, thiab nws cov lus qhia poob phaus kuj tau thov rau.

Thaum Lub Ob Hlis 4, 2026, Eli Lilly tshaj tawm nws daim ntawv qhia nyiaj txiag tag nrho rau xyoo 2025, nrog rau tag nrho cov nyiaj tau los ntawm $ 65.179 billion (+44%) rau xyoo. Kev siv nyiaj R&D txhua xyoo yog 13.337 billion US las (+21%), suav txog 20% ntawm tag nrho cov nyiaj tau los Los ntawm kev nthuav dav hauv cheeb tsam, xyoo 2025, Asmeskas cov nyiaj tau los ntawm kev lag luam yuav yog $ 43.481 billion ({11}}%), European cov nyiaj tau los ntawm kev ua lag luam yuav yog $ 11.558 billion ({2%). (+16%), Suav lag luam cov nyiaj tau los yuav yog $1.951 billion ({17}}%), thiab cov nyiaj tau los ntawm kev lag luam tseem tshuav yuav yog $6.057 billion ({19}}%). Los ntawm kev xav txog kev kho mob, Lilly tam sim no tsom mus rau plaub yam kab mob loj: ntshav qab zib, qog, tiv thaiv kab mob thiab paj hlwb.

Ntshav qab zib yog lub lag luam tseem ceeb ntawm Lilly. Raws li lub ntiaj teb lub qhov muag tshaj plaws -catching tshuaj, GLP-1R / GIPR agonist Tilpodide cov piam thaj txo Mouniaro thiab poob phaus Zepbound qhia muaj peev xwm nqus tau kub. Mouniaro qhov kev muag khoom txhua xyoo mus txog $ 22.965 billion (+99%), dhau los ua thawj cov khoom lag luam super blockbuster nrog cov nyiaj tau los txhua xyoo ntau dua $ 20 billion hauv lub tuam txhab keeb kwm. Zepbound cov nyiaj tau los txhua xyoo kuj tau txog $ 13.542 billion (+175%). Kev sib koom ua ke ntawm ob yam khoom no ib leeg tau tshaj $ 36.5 billion.

Cov khoom tseem ceeb Verzenio (CDK4/6 inhibitor) hauv thaj tsam ntawm oncology tau ua tiav txhua xyoo muag ntawm 5.723 billion US dollars (+8%). Eli Lilly yuav txhawb nqa ntau qhov kev sim tshuaj ntawm qhov ncauj GLP-1R agonist Orforglipron hauv 2026 thiab nce qib kev tswj hwm tseem ceeb ntawm Retatrutide (GLP-1R / GIPR / GCGR agonist).